Sign in →

Test Code DESPR Desipramine, Serum

Additional Codes

SUNQUEST:  DESPRM

EPIC:  LAB10303

Reporting Name

Desipramine, S

Useful For

Monitoring serum concentration of desipramine during therapy

 

Evaluating potential desipramine toxicity

 

May aid in evaluating patient compliance

Method Name

Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS)

Performing Laboratory

Mayo Clinic Laboratories in Rochester

Specimen Type

Serum Red


Specimen Required


Supplies: Sarstedt Aliquot Tube, 5 mL (T914)

Collection Container/Tube: Red top (Serum gel/SST are not acceptable)

Submission Container/Tube: Plastic vial

Specimen Volume: 1 mL

Collection Instructions:

1. Collect specimen immediately before next scheduled dose (minimum 12 hours after last dose).

2. Centrifuge and aliquot serum into a plastic vial. Serum must be separated from cells within 2 hours of collection.


Specimen Minimum Volume

0.25 mL

Specimen Stability Information

Specimen Type Temperature Time Special Container
Serum Red Refrigerated (preferred) 28 days
  Frozen  28 days
  Ambient  7 days

Reject Due To

Gross hemolysis Reject
Gross lipemia Reject
Gross icterus Reject

Reference Values

Therapeutic concentration: 100-300 ng/mL

 

Note: Therapeutic ranges are for specimens collected at trough (ie, immediately before next scheduled dose).

Levels may be elevated in non-trough specimens.

Day(s) Performed

Monday, Wednesday, Friday

CPT Code Information

80299

LOINC Code Information

Test ID Test Order Name Order LOINC Value
DESPR Desipramine, S 3531-1

 

Result ID Test Result Name Result LOINC Value
37123 Desipramine, S 3531-1

Clinical Information

Desipramine is a tricyclic antidepressant and a metabolite of imipramine. These drugs have also been employed in the treatment of enuresis (involuntary urination) in childhood and severe obsessive-compulsive neurosis. Desipramine is the antidepressant of choice in patients where maximal stimulation is indicated.

 

The therapeutic concentration of desipramine is 100 to 300 ng/mL. About 1 to 3 weeks of treatment are required before therapeutic effectiveness becomes apparent.

 

The most frequent side effects are those attributable to anticholinergic effects: dry mouth, constipation, dizziness, tachycardia, palpitations, blurred vision, and urinary retention. These occur at blood concentrations more than 400 ng/mL, although they may occur at therapeutic concentrations in the early stage of therapy. Cardiac toxicity (first-degree heart block) is usually associated with blood concentrations more than 400 ng/mL.

Specimen Retention Time

14 days

Report Available

3 to 5 days

Test Classification

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.

Forms

If not ordering electronically, complete, print, and send a Therapeutics Test Request (T831) with the specimen.